Skip to main content

Peer Review reports

From: Lutetium oxodotreotide ( 177 Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Original Submission
19 Jan 2020 Submitted Original manuscript
19 Nov 2020 Author responded Author comments - Jayne Smith-Palmer
15 Mar 2020 Reviewed Reviewer Report - Fabian Haupt
12 Jun 2020 Reviewed Reviewer Report
29 Sep 2020 Reviewed Reviewer Report
Resubmission - Version 2
19 Nov 2020 Submitted Manuscript version 2
1 Dec 2020 Author responded Author comments - Jayne Smith-Palmer
Resubmission - Version 3
1 Dec 2020 Submitted Manuscript version 3
Publishing
3 Dec 2020 Editorially accepted
5 Jan 2021 Article published 10.1186/s12885-020-07710-7

You can find further information about peer review here.

Back to article page